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ABC of palliative care
Difficult pain
Lesley Colvin, Karen Forbes, Marie Fallon
Pain occurs in up to 70% of patients with advanced cancer and
in about 65% of patients dying from non-malignant disease. In
about 10% of these patients the pain is difficult to control. Their
pain often falls into one of three categories: it responds poorly
to opioids, it is episodic and breaks through despite background
opioid analgesia, or it is caused by non-physical factors such as
psychosocial distress.
Pain that responds poorly to opioids
The European Association for Palliative Care guidelines on the
use of morphine and alternative opioids in cancer pain confirm
oral morphine as the opioid of choice for moderate to severe
pain. If the pain is uncontrolled with a dose of morphine that
gives the patient intolerable side effects, suggested measures
include exploring psychosocial issues, managing the side effects,
reducing the dose of opioid, switching to an alternative opioid,
or changing the route of administration. The use of adjuvant
drugs or co-analgesics may be appropriate. Many such patients
will have neuropathic pain.
Neuropathic pain
Nociceptive pain results from real or potential tissue damage.
Neuropathic pain is caused by damage to the peripheral or
central nervous system. Pain may be described as aching,
burning, shooting, or stabbing and may be associated with
abnormal sensation; normal touch is perceived as painful
(allodynia). It may be caused not only by tumour invasion or
compression but also by surgery, radiotherapy, and
chemotherapy. If neuropathic pain does not respond to opioids,
patients will require additional measures.
The early addition of adjuvant analgesics, such as a tricyclic
antidepressant or an anticonvulsant, should be considered. The
number needed to treat is 3 for both categories. There is no
evidence for a specific adjuvant for specific descriptors of
neuropathic pain.
In addition, there is no evidence for combining adjuvants.
The adjuvant should be chosen for an individual patient based
on all symptoms and potential side effects. Doses should be
This article is adapted from the second edition of the
ABC of Palliative Care, which will be published by
Blackwells in the autumn and available from
www.hammicksbma.com and all good medical
bookshops
Patients may be overwhelmed by their situation and the
central nervous system can express this as physical
pain. Social, psychological, or spiritual factors may be
major components of pain
Classic changes associated with a brachial plexopathy caused by right
Pancoast tumour: oedema, trophic changes, muscle wasting
Adjuvant analgesics*
Drug Dose Indications Side effects
Non-steroidal anti-inflammatories
(NSAID)—for example, diclofenac
50 mg oral every 8 hours (slow
release 75 mg every 12 hours);
100 mg per rectum once a day
Bone metastases, soft tissue
infiltration, liver pain,
inflammatory pain
Gastric irritation and bleeding, fluid
retention, headache; caution in renal
impairment
Steroids—for example,
dexamethasone
8-16 mg a day; use in morning;
titrate down to lowest dose that
controls pain
Raised intracranial pressure,
nerve compression, soft
tissue infiltration, liver pain
Gastric irritation if used with NSAID,
fluid retention, confusion, Cushingoid
appearance, candidiasis, hyperglycaemia
Gabapentin 100-300 mg nightly (starting dose)
(titrate to 600 mg every 8 hours;
higher dose may be needed)
Nerve pain of any cause Mild sedation, tremor, confusion
Amitriptyline (evidence for all
tricyclics)
25 mg nightly (starting dose)
10 mg nightly (in elderly patients)
Nerve pain of any cause Sedation, dizziness, confusion, dry
mouth, constipation, urinary retention;
avoid in patients with cardiac disease
Carbamazepine (evidence for all
anticonvulsants)
100-200 mg nightly (starting dose) Nerve pain of any cause Vertigo, sedation, constipation, rash
*Drugs with a primary indication other than pain, but analgesic when used as above.
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titrated to balance analgesia with adverse effects. If titration has
reached a limit and pain has only partially responded then a
second adjuvant may be added in some cases. This usually
means a reduction in the dose of the first. A common example
of combining adjuvants is gabapentin, which at maximum
tolerated dose can sometimes be reduced to allow the addition
of amitriptyline.
Non-pharmacological techniques
There are several non-pharmacological techniques for the
management of neuropathic pain.
Psychological techniques—Psychological techniques, such as
cognitive behavioural therapies, include simple relaxation,
hypnosis, and biofeedback. These methods focus on overt
behaviour and underlying cognitions and train the patient in
coping strategies and behavioural techniques. Simple relaxation
techniques should also not be forgotten.
Acupuncture has been used successfully in Eastern medicine
for centuries. It seems to release endogenous analgesics within
the spinal cord. Acupuncture is particularly useful for
myofascial pain, which is a common secondary phenomenon in
many cancer pain syndromes.
Transcutaneous electrical nerve stimulation (TENS) may have a
similar mechanism of action to acupuncture. There is evidence
to support its use in both acute and chronic pain.
Herbal medicine and homoeopathy are widely used for pain, but
often with little evidence for efficacy. Regulations on safety for
these treatments are limited compared with those for
conventional drugs, and doctors should be wary of
unrecognised side effects.
Episodic pain
The term episodic pain is used to describe any acute transient
pain that is severe and has an intensity that flares over baseline.
Episodic pain thus encompasses breakthrough pain and
incident pain. Breakthrough pain includes pain returning
before the next dose of opioid is due or acute exacerbations of
pain occurring on the background of pain usually controlled by
an opioid regimen. Incident pain is usually defined as that
occurring due to a voluntary action, such as movement or
passing urine or stool. Pain due to bony metastases exacerbated
by movement or weight bearing can be particularly
problematic.
Incident pain
Patients with bony metastases in the spine, pelvis, or femora
may have pain that escalates on movement, walking, standing,
or even sitting. Opioid analgesics along with non-steroidal
anti-inflammatory drugs are the mainstay of treatment, with the
aim of making the patient comfortable at rest. Increasing the
opioid dose is often unhelpful as a dose sufficient to make
movement possible is too sedating when the patient is resting.
Rescue or breakthrough doses of normal release opioid are
usually used in anticipation of movement, along with non-drug
measures such as radiotherapy, possible surgery, and
appropriate aids and appliances.
Bisphosphonates are established in the prevention of
skeletal events due to metastases from most solid tumours. In
some patients, they provide short term analgesia.
Methadone
Before invasive techniques are considered, it is important to
exclude untreated depression, general anxiety, and distress
(though untreated pain may also lead to any or all of these).
Transcutaneous electrical stimulation may help patients with neuropathic
pain that does not respond to opioids
Radiographs showing lystic lesions in femur (left) and internal stabilisation
of bone (right)
Computed tomogram of pelvis showing advanced pelvic disease from
colorectal tumour resulting in severe pain
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It is also worth considering a different drug. Methadone
deserves a special mention in this context. It has unusual
properties, which we do not fully understand. Its receptor
binding profile differs from that of pure  agonists and it can be
remarkably potent at small doses.
Methadone often gives much better analgesia and reduced
side effects. In addition, difficult elements of a pain—such as
neuropathic or incident pain, or both—may become easier to
control.
Invasive analgesic techniques
Despite appropriate use of analgesia and non-drug therapies,
chemotherapy, and radiotherapy by multidisciplinary teams, a
considerable number of patients will still have uncontrolled
pain or unacceptable side effects, or both.
Such patients should be considered for some form of
invasive analgesic technique. This may range from a simple
nerve block to more invasive techniques such as regional or
neurodestructive blocks.
The choice of technique is influenced by:
x Patient’s expectations
x Prognosis and required duration of analgesia
x Pathology
x Availability of experts and trained staff.
A basic rule is that the technique with the least likelihood of
severe side effects should be chosen. In general, neurodestructive
techniques should be reserved for when other measures have
failed or when life span is obviously limited.
Spinal routes of drug delivery
With improvements in catheter and pump technology, use of
spinal lines is becoming more common in pain control. If the
technique is carried out by trained staff, complication rates are
low, allowing flexible, long term analgesia that can be used in an
outpatient setting. Catheters can be inserted either into the
epidural space or into the subarachnoid (intrathecal) space,
where the cerebrospinal fluid is found. The line may be
tunnelled subcutaneously to reduce risks of infection and
movement of the catheter. The choice of technique depends on
several factors.
The future
Agents not currently widely available in the UK that may be
helpful in managing patients with cancer pain include:
x Lidocaine patches are available in the US but limited in the
UK. They produce few side effects and studies have shown
efficacy in neuropathic pain. We have also used them for bone
pain, particularly vertebral metastases, with some success.
x Pregabalin has a similar pharmacological profile to
gabapentin but is more potent. Randomised controlled trials
have shown efficacy against some forms of neuropathic pain
and an improved sleep pattern. Titration of dose is easier than
with gabapentin.
x N-methyl-D-aspartate (NMDA) subtype selective agents—Currently
available drugs are non-selective. Animal research suggests
particular subtypes of the NMDA receptor may have potential
for analgesia with reduced side effects and opioid sparing
effects.
x Calcitonin gene-related peptide (CGRP) antagonists—CGRP is
found in sensory neurones. Non-peptide analogues with a
favourable pharmacokinetic profile may have potential as
analgesics.
Starting or switching to methadone can be complicated
in some patients, and specialist advice should usually be
sought
Examples of invasive analgesic techniques
Peripheral
Peripheral nerve block
x Intercostal
x Femoral
x Sciatic
Major nerve block
x Brachial plexus
x Psoas
x Paravertebral sensory nerve root
ablation
x Coeliac plexus
Central
Non-destructive
x Epidural
x Intrathecal
Neurosurgical/destructive
x Rhizotomy
x Cordotomy
x Intrathecal phenol
Factors affecting choice of spinal route of delivery
Epidural Intrathecal
Procedural
x Simple procedure—local
anaesthetic with or without
sedation
x Fixation can be difficult
x Catheters not designed for long
term use
x Drug spread may be limited,
especially if there is tumour in
the epidural space, or scarring
related to radiotherapy
x Safety—catheter migration to
intrathecal space delivering
potential overdose
x Sedation or general
anaesthesia usually required
x Deep fixation at time of
insertion
x Silastic catheter designed for
long term use
x Drug spreads within CSF,
unless obstruction to flow;
lipid solubility determines
degree of spread
x Safety—catheter can only
migrate out of intrathecal
space
Prognosis
Short term use:
x Limited prognosis
x Other definitive treatment
planned—for example,
radiotherapy
x Trial for intrathecal line
Longer term use:
x Several different options—for
example, external or fully
implantable
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